表紙:医薬品新興国の世界市場:業界動向、シェア、規模、成長、機会、予測(2021年~2026年)
市場調査レポート
商品コード
1037013

医薬品新興国の世界市場:業界動向、シェア、規模、成長、機会、予測(2021年~2026年)

Pharmerging Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日: | 発行: IMARC Services Private Limited | ページ情報: 英文 143 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.77円
医薬品新興国の世界市場:業界動向、シェア、規模、成長、機会、予測(2021年~2026年)
出版日: 2021年11月10日
発行: IMARC Services Private Limited
ページ情報: 英文 143 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の医薬品新興国市場規模は、2015年から2020年にかけて力強い成長を示し、2021年から2026年の間に10.4%のCAGRで成長すると予想されています。

現在、私立病院の増加に伴う医療費の増加が、世界の同市場の成長を後押ししています。また、多くの慢性疾患の高い有病率と、疾患の早期発見および早期治療に対する消費者の意識が高まっていることも、市場の成長をさらに後押ししています。さらに、慢性疾患の治療費を削減するための政府政策や償還制度が各国で導入されていることも、市場の成長を後押ししています。

そして、自己負担額を減らすために、医薬品新興国の国々で多数の保険を提供している保険企業の数が増加しており、これらの国々の医薬品需要をさらに高めています。これとは別に、先進治療を導入するためのバイオテクノロジー、免疫学、腫瘍学などの分野での大規模な研究開発活動への投資増加も、市場の成長を促しています。

当レポートでは、世界の医薬品新興国市場について調査し、市場の概要・COVID-19の影響、製品別・適応症別・流通チャネル別・国別の市場分析、競合情勢、主要企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の医薬品新興国市場

  • 市場概要
  • 市場パフォーマンス
  • COVID-19の影響

第6章 市場セグメンテーション:製品別

  • 医薬品
    • 主な種類
  • ヘルスケア
    • 主な種類

第7章 市場セグメンテーション:適応症別

  • 生活習慣病
  • がん・自己免疫疾患
  • 感染症
  • その他

第8章 市場セグメンテーション:流通チャネル別

  • 病院
  • 小売薬局
  • オンラインストア
  • その他

第9章 市場セグメンテーション:国別

  • ティアI
    • 中国
  • ティアII
    • インド
    • ブラジル
    • ロシア
    • 南アフリカ
  • ティアIII
    • アルゼンチン
    • メキシコ
    • ポーランド
    • ウクライナ
    • トルコ
    • サウジアラビア
    • エジプト
    • アルジェリア
    • ナイジェリア
    • タイ
    • インドネシア
    • パキスタン
    • その他

第10章 SWOT分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Sanofi S.A.
    • Pfizer Inc.
    • AstraZeneca Plc.
    • GlaxoSmithKline Plc.
    • F. Hoffmann-La Roche AG (Roche AG)
    • Eli Lilly and Company
    • Johnson & Johnson
    • Abbott Laboratories
    • Novartis AG
    • Teva Pharmaceutical Limited
目次
Product Code: SR1020G31_Report

The global pharmerging market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 10.4% during 2021-2026. Pharmerging refers to a group of countries that hold low positioning in the pharmaceutical market but have a speedy growth. Some of the key pharmerging markets include China, India, Brazil, Russia, South Africa, Mexico, Indonesia, Turkey, etc.

The increasing healthcare expenditures along with the rising number of private hospitals are currently propelling the global pharmerging market growth. Additionally, the high prevalence of numerous chronic diseases and growing consumer awareness towards early disease detection and treatment procedures are further augmenting the market growth. Moreover, the increasing geriatric population, who are more prone to serious medical conditions, such as dementia, hypertension, cardiac failure, etc., is also bolstering the demand for pharmaceuticals. Additionally, the introduction of government policies and reimbursement schemes across various countries for reducing the cost of treatment for chronic diseases is also propelling the market growth. Moreover, the growing number of insurance companies in the pharmerging countries offering numerous insurance policies to decrease the out-of-the-pocket expenditures is further augmenting the demand of pharmaceuticals in these countries. Apart from this, the rising investments in extensive R&D activities in the fields of biotechnology, immunology, oncology, etc., for the introduction of advanced treatments are also catalyzing the market growth.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmerging market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, product outlook, indication and distribution channel.

Breakup by Product Outlook:

  • Pharmaceuticals
  • Patented Prescription Drugs
  • Generic Prescription Drugs
  • OTC Drugs
  • Healthcare
  • Medical Devices
  • Clinical Diagnosis
  • Others

Breakup by Indication:

  • Lifestyle Diseases
  • Cancer and Autoimmune Diseases
  • Infectious Diseases
  • Others

Breakup by Distribution Channel:

  • Hospitals
  • Retail Pharmacies
  • Online Stores
  • Others

Breakup by Country:

  • Tier I
  • China
  • Tier II
  • India
  • Brazil
  • Russia
  • South Africa
  • Tier II
  • Argentina
  • Mexico
  • Poland
  • Ukraine
  • Turkey
  • Saudi Arabia
  • Egypt
  • Algeria
  • Nigeria
  • Thailand
  • Indonesia
  • Pakistan
  • Others

Competitive Landscape:

  • The competitive landscape of the industry has also been examined with some of the key players being Sanofi S.A., Pfizer Inc., AstraZeneca Plc, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG (Roche AG), Eli Lilly and Company, Johnson & Johnson, Abbott Laboratories, Novartis AG and Teva Pharmaceutical Limited.

Key Questions Answered in This Report:

  • How has the global pharmerging market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What is the impact of COVID-19 on global pharmerging market?
  • What is the breakup of the market based on the product outlook?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the market?
  • What is the structure of the global pharmerging market and who are the key players?
  • What is the degree of competition in the market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pharmerging Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Pharmaceutical
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Patented Prescription Drugs
      • 6.1.2.2 Generic Prescription Drugs
      • 6.1.2.3 OTC Drugs
    • 6.1.3 Market Forecast
  • 6.2 Healthcare
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Medical Devices
      • 6.2.2.2 Clinical Diagnosis
      • 6.2.2.3 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Indication

  • 7.1 Lifestyle Diseases
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cancer and Autoimmune Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Infectious Diseases
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Country

  • 9.1 Tier I
    • 9.1.1 China
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
  • 9.2 Tier II
    • 9.2.1 India
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Brazil
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 Russia
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Africa
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
  • 9.3 Tier III
    • 9.3.1 Argentina
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 Mexico
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 Poland
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Ukraine
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Turkey
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Saudi Arabia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Egypt
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
    • 9.3.8 Algeria
      • 9.3.8.1 Market Trends
      • 9.3.8.2 Market Forecast
    • 9.3.9 Nigeria
      • 9.3.9.1 Market Trends
      • 9.3.9.2 Market Forecast
    • 9.3.10 Thailand
      • 9.3.10.1 Market Trends
      • 9.3.10.2 Market Forecast
    • 9.3.11 Indonesia
      • 9.3.11.1 Market Trends
      • 9.3.11.2 Market Forecast
    • 9.3.12 Pakistan
      • 9.3.12.1 Market Trends
      • 9.3.12.2 Market Forecast
    • 9.3.13 Others
      • 9.3.13.1 Market Trends
      • 9.3.13.2 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Sanofi S.A.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Pfizer Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 AstraZeneca Plc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 GlaxoSmithKline Plc.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.3 SWOT Analysis
    • 13.3.5 F. Hoffmann-La Roche AG (Roche AG)
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Eli Lilly and Company
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Johnson & Johnson
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Abbott Laboratories
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Novartis AG
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Teva Pharmaceutical Limited
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financial
      • 13.3.10.4 SWOT Analysis